Europe Next-generation Sequencing Market

The Europe next-generation sequencing market is anticipated to reach USD 8.88 billion by 2030 from USD 4.42 billion in 2025, at a CAGR of 15.0%.

The key growth drivers of the Europe next-generation sequencing market are sustained public and private funding for genomics, as well as the scaling up of players in sequencing capacity across healthcare systems and research infrastructures.

The Europe next-generation sequencing market is consolidated. The major participants operating in the Europe next-generation sequencing market are Illumina, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), and Danaher Corporation (US), among others.

To know about the assumptions considered for the study download the pdf brochure

In July 2024, F. Hoffmann-La Roche Ltd. acquired Point of Care Technology from LumiraDx (UK) to support its multi-assay point-of-care platform. In May 2024, Oxford Nanopore Technologies, in collaboration with others, launched a new Pharmacogenomics Beta Programme. This long-read PGx solution, available for research use, is designed to provide unambiguous genetic results in a single end-to-end workflow from sample to PGx star allele call.

Illumina, Inc. is one of the leading companies in the Europe next-generation sequencing market, providing integrated genomic solutions that enable the analysis of genetic variation and biological function across research, clinical, and translational settings. The company's regional portfolio includes sequencing instruments, consumables, and informatics platforms, such as cloud-based analysis and run-management software, designed to simplify NGS workflows and support applications ranging from oncology and rare diseases to reproductive health and population genomics. Illumina supports sequencing and instrument service plans in Europe, training through Solutions Centers, and workflow-evaluation services to help laboratories adopt and scale NGS. At the same time, sustained R&D investment extends accuracy, throughput, and automation and expands validated offerings under evolving European regulatory frameworks.

Thermo Fisher Scientific Inc. It is one of the leading players in the Europe next-generation sequencing market, having consolidated a strong direct presence with an established distributor network across the EU-5, Nordics, and key Central & Eastern European countries to support academic centers, reference laboratories, and biopharma customers. In recent years, it has made substantial efforts to strengthen its portfolio for Europe NGS through the Ion Torrent Genexus System, which automates the end-to-end NGS workflow; the Ion AmpliSeq SARS-COV-2 research assays for viral surveillance; and the Ion Torrent Oncomine Myeloid MRD and other oncology assays for hematology and solid-tumor research. In 2024, Thermo Fisher also launched the Applied Biosystems Axiom BloodGenomiX Array and software, which could enable high-throughput, precise blood group genotyping that would further support safer transfusion research programs in European blood centers and hospital laboratories, thus reinforcing the competitive position in the Europe next-generation sequencing market.

F. Hoffmann-La Roche Ltd. is one of the key players in the Europe next-generation sequencing (NGS) market. The company builds on its strong diagnostics footprint and close ties with major Europe cancer centers and university hospitals, offering a broad portfolio of AVENIO and KAPA-branded NGS products. In recent years, Roche has focused on comprehensive genomic profiling and liquid-biopsy solutions, launching the AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit and automated CGP workflows on the AVENIO Edge system, alongside AVENIO ctDNA Targeted, Expanded, and Surveillance Kits for plasma-based oncology research. Its KAPA HyperPrep and related library-prep chemistries further strengthen Roche’s position in sample-prep and automation-ready workflows. Through Foundation Medicine, Roche also provides clinically validated comprehensive genomic profiling services that are increasingly adopted by European oncologists, reinforcing the company’s competitive position in NGS products and services across the region.

Market Ranking

The Europe NGS market is highly competitive, with a few global suppliers capturing a large share of regional spend. At the same time, a long tail of local players and service providers addresses country-specific needs. Illumina holds a leading position with its broad NovaSeq, NextSeq, and MiSeq platforms, as well and associated consumables and informatics, which are widely installed across European university hospitals, reference labs, and population-genomics initiatives. Thermo Fisher Scientific is another key participant, offering integrated Ion Torrent–based workflows, targeted oncology and infectious-disease panels, and automation-ready library-prep solutions that appeal to medium-throughput clinical and translational labs. F. Hoffmann-La Roche complements these players with sequencing platforms, oncology-focused assays, and strong ties to clinical diagnostics customers, reinforcing its position in cancer and hereditary disease applications. Beyond these leaders, the ecosystem includes regional champions such as QIAGEN, Oxford Nanopore Technologies, Eurofins, and other specialized service, sample-prep, and bioinformatics firms, making the market fragmented yet vibrant. Recent trends indicate strong momentum toward end-to-end workflows, higher automation, and cloud-based analytics tailored to European data-protection rules, as vendors compete on ease of use, turnaround time, and total cost of ownership to support the expanding adoption of NGS across European healthcare and biopharma.

Related Reports:

Europe Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com